We are laser-focused on our mission: to improve the lives of patients and their families.

Clinical Trials

Our pipeline programs target kidney diseases of high unmet need, including ADPKD.

Programs

We are targeting the underlying biology of these diseases with a novel and potentially powerful approach: MicroRNA-based therapeutics.

Technology

News.

September 20, 2023

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

September 13, 2023

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

September 5, 2023

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

MORE NEWS